Best in Biotech 30 Dec 2019
European Biotech’s Top News in 2019
With the year coming to a close, it’s time to review the most important biotech news events that took place in the European biotech industry in 2019. It has been…
RNA technology
- Latest Posts
In Depth 1 Mar 2021
How Are European Biotechs Tackling the Cardiovascular Disease Problem?
Cardiovascular diseases may not regularly grab the headlines, but they’re the leading cause of mortality globally, making up over 30% of all deaths worldwide. While there are many established treatments…
Interview 3 Jul 2019
Meet the First Company in the Brand New Field of Epitranscriptomics
A whole new therapeutic area is taking medical research by storm. In Cambridge, UK, the company Storm Therapeutics is leading the development of the first treatments to target a new…
News and Trends 14 May 2019
RNAi Therapy Smashes Solid Tumors in Preclinical Tests
Developed by the UK biotech Celixir, a therapy based on silencing genes with RNA molecules in a process called RNAi has shrunk tumors by 50% in culture. Although there are…
ADVERTISEMENT
News and Trends 11 Dec 2018
UK Biotech Settles Lawsuit on the First RNAi Drug
Silence Therapeutics and Alnylam have reached a settlement that puts an end to a legal dispute between them resulting in Silence receiving some royalties on Onpattro, the first RNA interference…
News and Trends 25 Nov 2019
Novartis Enters RNA Therapeutics with Medicines Company Merger
Novartis is to acquire The Medicines Company and its late-stage RNA interference drug designed to protect against cardiovascular disease in twice-yearly shots. Novartis will pay €8.8B ($9.7B) to acquire The…
News and Trends 20 Sep 2018
RNA Therapy Shows Promise for Treating Liver Cancer
British biotech MiNA Therapeutics’ innovative RNA treatment may enhance liver cancer patients’ response to standard cancer therapies, suggest early results from a Phase I/IIa clinical trial. When they received the…
News and Trends 30 Aug 2018
First RNAi Drug Approved in Europe After 20 Years of Research
The first ever RNA interference (RNAi) drug, used to treat polyneuropathy in patients with hereditary transthyretin-mediated amyloidosis, has been given marketing approval by the European Commision. The approval follows that…
News and Trends 5 Sep 2018
RNA Therapy Improves Vision in Patients with Rare Genetic Blindness
Dutch company ProQR has released data from a Phase I/II trial showing its RNA therapy can improve the vision of people with a rare form of hereditary blindness. The…
News and Trends 6 Aug 2018
New Gene Therapy Could Treat Cystic Fibrosis With One Dose
A new partnership in the UK will develop a gene therapy for cystic fibrosis that could treat the disease with a single dose. Cystic fibrosis is a genetic disease that…
Interview 12 Mar 2018
A Dutch Company on the Quest Against Cystic Fibrosis
ProQR is the result of a personal quest against cystic fibrosis started by its CEO, Daniel de Boer. Interested in his story and the company's unique approach to treating the…
News and Trends 6 Mar 2018
French Biotech Uses Natural Peptides to Boost Plant Growth and Immunity
Micropep Technologies, a Toulouse-based biotech, has raised €4M to develop peptides that boost plant growth and disease resistance by regulating gene expression. Micropep Technologies has raised a Series A funding with the…
